Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: Assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations

Journal of Clinical Pharmacology

Volumn 53, Issue 2, 2013, Pages 217-227

  Yang, Zheng ^a   Vakkalagadda, Blisse ^a   Shen, Guoxiang ^a   Ahlers, Christoph M ^a   Has, Teresa ^a   Christopher, Lisa J ^a   Kurland, John F ^a   Roongta, Vikram ^a   Masson, Eric ^a   Zhang, Steven ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

BMS 690514; CYP3A4 inhibition; Drug drug interaction; Ketoconazole; P glycoprotein inhibition; Pharmacokinetics; Physiologically based modeling and simulation; Simcyp software

Indexed keywords

BMS 690514; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DIARRHEA; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; GENETIC POLYMORPHISM; GENOTYPING TECHNIQUE; HUMAN; INTESTINE; KIDNEY; LIVER; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NORMAL HUMAN; RASH; SIMULATION; SINGLE DRUG DOSE; SOMNOLENCE;

ADULT; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; COMPUTER SIMULATION; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; GENOTYPE; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PIPERIDINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRROLES; TRIAZINES; YOUNG ADULT;

EID: 84877846515     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270012439208     Document Type: Article

References (30)

1. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med . 1999;77:527-543.
2. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer . 2005;5:341-354.
3. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res . 2007;5:203-220.
4. Pennell NA, Lynch TJ Jr. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist . 2009;14:399-411.
5. Gerard C, Debruyne C. Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer. Mol Oncol . 2009;3:409-424.
6. Wong TW, Lee FY, Emanuel S, et al. Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families. Clin Cancer Res . 2011;17:4031-4141.
7. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med . 2005;352:786-792.
8. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med . 2005;2:e73. doi:10.1371/journal.pmed. 0020073.
9. Wong TW, Fargnoli J, Malone H, et al. Preclinical and clinical antiangiogenic activity of BMS-690514. Presented at: the 35th ESMO Congress; October 8-12, 2010; Milan, Italy.
10. Christopher LJ, Hong H, Vakkalagadda B, et al. Metabolism and disposition of [14C]BMS-690514 ((3R,4R)-4-amino-1-((4-((3-methoxyphenyl)amino)pyrrolo[2,1- f][1,2,4]triazin-5-yl)methyl)-3-piperidinol), an ErbB/VEGFR inhibitor, after oral administration to humans. Drug Metab Dispos . 2010;38:2049-2059.
11. Hong HZ, Su H, Ma L, et al. In vitro characterization of the metabolic pathways and P450 inhibition and induction potential of BMS-690514, an ErbB/VEGFR inhibitor. Drug Metab Dispos . 2011;39:1658-1667.
12. Marathe P, Tang Y, Sleczka B, et al. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci . 2010;98:3579-3593.
13. US Food and Drug Administration. FDA Draft Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling . Rockville, MD: US Food and Drug Administration; 2006.
14. European Medicines Agency. MEA Draft Guideline on the Investigation of Drug Interactions . London, UK: European Medicines Agency; 2010.
15. Choo EF, Leake B, Wandel C, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos . 2000;28:655-660.
16. Chien JY, Lucksiri A, Ernest CS, Gorski JC, Wrighton SA, Hall SD. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos . 2006;34: 1208-1219.
17. Sbar E, Wong T, Salvati M, et al. Preclinical and clinical activity of BMS-690514 in the treatment of non-small cell lung cancer (NSCLC). Ann Oncol . 2010;21:119P.
18. Zhang H, Sinz MW, Rodrigues AD. Metabolism-mediated drugdrug interactions. In: Zhang D, Zhu M, Humphreys WG, eds. Drug Metabolism in Drug Design and Development . New York: John Wiley; 2008:116-119.
19. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics . 1999;9:669-682.
20. Chou WH, Yan FX, Robbins-Weilert DK, et al. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem . 2003;49:542-551.
21. Brockmler J, Kirchheiner J, Meisel C, Roots I. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics . 2000;1: 125-151.
22. Vakkalagadda B, Park JS, Ahlers CM, et al. Food increased the bioavailability of BMS-690514, an orally active EGFR/HER2/VEGF receptor kinase inhibitor, in healthy subjects. J Clin Pharmacol . 2011 Oct 26 [Epub ahead of print]. doi:10.1177/0091270011417826.
23. Zhang S, Zhou S, Heller K, et al. A model-based assessment of the effect of covariates on the pharmacokinetics of BMS-690514 in cancer patients. Presented at: ACCP Annual Meeting; September 13-15, 2009; San Antonio, TX. Abstract 059.
24. Rodgers T, Rowland M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res . 2007;24:918-933.
25. Nizoral (ketoconazole) [package insert]. Titusville, NJ: Janssen Pharmaceutica; 2002.
26. Wandel C, Kim RB, Guengerich FP, Wood AJ. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab Dispos . 2000;28:895-898.
27. Hsiao P, Bui T, Ho RJ, Unadkat JD. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier. Drug Metab Dispos . 2008;36:481-484.
28. Gupta A, Unadkat JD, Mao Q. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J Pharm Sci . 2007;96:3226-3235.
29. Allegra (fexofenadine hydrochloride) [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2006.
30. Cubitt HE, Yeo KR, Howgate EM, Rostami-Hodjegan A, Barter ZE. Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica . 2011;41:623-638.